OMI HCMO Redaction Log:

We respectfully request highly confidential treatment under all applicable statutes, rules, and regulations. Without prejudice to the rights of OMI or Rotech, if Oregon Health Authority or Department of Justice should at any time contemplate disclosing any such materials to the public or to any third party for any reason and for any use—including but not limited to quoting from, attaching, or otherwise referring to such documents in a court or administrative proceeding whether filed under seal or publicly—we request an opportunity of no fewer than three days advance notice to allow sufficient time to object and, if necessary, seek protections against disclosure from a court of competent jurisdiction.

Bates Reference	Item #	Information Redacted	Reason for Redaction	Statutory Basis
HCMO_SUBMISSION_00862	Supplemental Responses Question 6(a)	The parties have confidentially filed a response to OHA's supplemental request question 6.	The confidential information is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information. The confidential information was submitted to the OHA in confidence, is not publicly available, is not otherwise required to be submitted, the OHA has obliged itself in good faith not to disclose the information, and the public interest would suffer by discouraging frank communication with agencies.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence

Bates Reference	Item #	Information Redacted	Reason for Redaction	Statutory Basis
HCMO_SUBMISSION_00865 HCMO_SUBMISSION_00866	Supplemental Responses Question 9(a)-(d) and the requested documents	The parties have confidentially filed a response to OHA's supplemental request number 9, which requested attorneyclient privileged information and the underlying privileged documents developed during due diligence. The parties have redacted the response to question 9.	The documentation is being withheld on the basis of attorney-client privilege because it contains advice of outside counsel at Kirkland & Ellis LLP concerning legal due diligence. The responses are being redacted because they contain confidential information that is known to a limited number of OMI and Rotech Directors and Officers, are not otherwise publicly disclosed, and have commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information.	ORS 415.501(13)(c) ORS § 40.225 – Attorney-Client Privilege ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence
HCMO_SUBMISSION_00866 HCMO_SUBMISSION_00867	Supplemental Responses Question 10(a)-(c)	The parties have confidentially filed a response to OHA's supplemental request question 10 and have redacted their responses to question 10.	The confidential information is being redacted because it is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information. The confidential information was submitted to the OHA in confidence, is not publicly available, is not otherwise required to be submitted, the OHA has obliged itself in good faith not to disclose the information, and the public interest would suffer by discouraging frank communication with agencies.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence

Bates Reference	Item #	Information Redacted	Reason for Redaction	Statutory Basis
HCMO_SUBMISSION_00867	Supplemental Responses Question 13	Due to the reasons and statutes provided to the right, the parties have not provided due diligence, reports, presentations, competitive analyses, market research, or data developed by or created for OMI or Rotech, including by third parties, between January 1, 2022, and December 31, 2024, related to the nationwide or Oregon markets for home medical equipment or DME products.	Reports requested relating to competitive analyses, market research, and data created for OMI are being withheld on the basis of attorney-client privilege because they contain advice of outside counsel at Kirkland & Ellis LLP concerning legal due diligence. The confidential information is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information.	ORS \$192.355(4) – Information Submitted to a Public Body in Confidence ORS \$ 40.225 – Attorney- client privilege ORS \$ 192.355(8) Prohibited Under Federal Law
HCMO_SUBMISSION_00870 HCMO_SUBMISSION_00872	Exhibit 6 to the Supplemental Responses	The parties have confidentially filed Oregon financial data for OMI and Rotech subsidiaries. OMI and Rotech have redacted this data in the public filing.	The confidential information is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence ORS § 192.355(8) Prohibited Under Federal Law

Bates Reference	Item #	Information Redacted	Reason for Redaction	Statutory Basis
HCMO_SUBMISSION_00876 HCMO_SUBMISSION_00890	Exhibit 11 -Rotech Quality Metrics and Customer Satisfaction Data	The parties have confidentially filed service quality metrics and customer satisfaction data for Rotech. The parties have redacted this data in the public filing.	The confidential information was submitted to the OHA in confidence, is not publicly available, is not otherwise required to be submitted, the OHA has obliged itself in good faith not to disclose the information, and the public interest would suffer by discouraging frank communication with agencies. The confidential information is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence ORS § 192.355(8) Prohibited Under Federal Law
HCMO_SUBMISSION_00892 HCMO_SUBMISSION_00896	Exhibit 12 -OMI Quality Metrics and Customer Satisfaction Data	The parties have confidentially filed service quality metrics and customer satisfaction data for OMI's Patient Direct segment. The parties have redacted this data in the public filing.	The confidential information was submitted to the OHA in confidence, is not publicly available, is not otherwise required to be submitted, the OHA has obliged itself in good faith not to disclose the information, and the public interest would suffer by discouraging frank communication with agencies. The confidential information is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence ORS § 192.355(8) Prohibited Under Federal Law

Bates Reference	Item #	Information Redacted	Reason for Redaction	Statutory Basis
HCMO_SUBMISSION_00899 HCMO_SUBMISSION_00900	Supplemental Materials	Responses to OHA Information Requests	The confidential information was submitted to the OHA in confidence, is not publicly available, is not otherwise required to be submitted, the OHA has obliged itself in good faith not to disclose the information, and the public interest would suffer by discouraging frank communication with agencies. The confidential information is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence
HCMO_SUBMISSION_00902 HCMO_SUBMISSION_01915	Supplemental Materials	Pre-Merger Notification Filing Attachments	The confidential information is being redacted because it is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, the parties are requesting further confidential treatment of these materials.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence

Bates Reference	Item #	Information Redacted	Reason for Redaction	Statutory Basis
HCMO_SUBMISSION_01916 HCMO_SUBMISSION_02004	Supplemental Materials	Pre-Merger Notification Filing Attachments	The confidential information is being redacted because it is known to a limited number of OMI and Rotech Directors and Officers, is not otherwise publicly disclosed, and has commercial value that gives the producing parties the opportunity to obtain a business advantage over competitors that do not know this information. Portions of reports requested relating to competitive analyses, market research, and data created for OMI are being withheld on the basis of attorney-client privilege because they contain advice of outside counsel at Kirkland & Ellis LLP concerning legal due diligence. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, the parties are requesting further confidential treatment of these materials.	ORS 415.501(13)(c) ORS 192.345(2) – Trade Secrets ORS § 192.355(4) – Information Submitted to a Public Body in Confidence Attorney-Client Privilege